🧬 Winners, Losers, and Upcoming Earnings Calls
Merck gets beaten at it’s own game, BMS lands another CAR-T indication, Otsuka dives into digital therapeutics, and "hub-and-spoke" biotech raises $73M.
FDA approvals for Amgen and Tris Pharma, BMS' $80M global licensing spend, BioNTech continues Africa push with $145M, and Novo Nordisk blames the American Healthcare System
Pfizer naps a Priority Review Voucher, 3 separate $1B+ acquisitions, Insmed stock doubles on Ph3 results, and Takeda begins restructuring with 600+ layoffs.
ASCO news up the wazoo, CAR-T attacks solid tumors, the first reported case of diabetes cured by cell therapy, and positive Ph1/2 data turns sour on safety profile.
Takeda's sticky $1.2B partnership, two new funds totally $350M+, Adderall no longer in short supply, two big pharmas ordered to pay Hawaii nearly $1B
Pfizer plans another $1.5B in cuts, biotech launches with aim to shed fat (but not muscle), Otsuka ditches an Alzheimer's med, and Novo Nordisk is on fire (again).
AstraZeneca sets $80B by 2023 sales targets, two antibody fundraises totalling $345M, and Eli Lilly gets deeper into radiopharma while Astellas gets into automated cell therapy manufacturing.
Cell therapy history was made, FDA approves first two Eylea biosimilars, Gilead's $4.3B liver disease bet yields positive ph3 data, and a trilogy of lung disease positive trial data.
Bayers posts hot menopause clinical trial results, Moderna wins a major lawsuit against Pfizer-BioNTech, and a molecular glue biotech unsticks some staff
BMS lands new CAR-T accelerated approval, Roche's $2.7B obesity bet has early win, Eli Lilly leads in revenue growth, and J&J pays $850M for atopic dermatitis biotech.
